Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02210065 · ClinicalTrials.gov registry record · Phase 2
Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02210065: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02210065 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02210065, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who receive an allogeneic stem cell transplant. Researchers also want to learn about the safety of giving CTLs to patients who have had a stem cell transplant.
Interventions
- BIOLOGICAL Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-03-03 |
| Est. Completion | 2019-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02210065
The ClinicalTrials.gov registry entry for NCT02210065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) is the first listed.
NCT02210065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02210065 about?
NCT02210065 is a clinical study titled "Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation". The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who receive an allogeneic stem cell transplant. Researchers also want to learn about the safety of giving CTLs to patients who hav...
What is the current status of trial NCT02210065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-03-03. Estimated completion is 2019-05-13.
What interventions are being tested in trial NCT02210065?
The interventions under investigation include: Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02210065?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.